ABSTRACT
Primary squamous cell carcinoma (SCC) associated with ovarian endometriosis is extremely rare and has a poor prognosis due to insufficient information on the optimal postoperative treatment. Here, we describe the response of this tumor to the administration of paclitaxel-carboplatin. A 45-year-old woman diagnosed with stage IIIc primary SCC of the ovary associated with endometriosis underwent optimal surgery followed by six courses of chemotherapy at 3-week intervals with paclitaxel and carboplatin. She tolerated the chemotherapy well and remained without evidence of disease during first-line chemotherapy. Two months later, she was readmitted with recurrence of a pelvic tumor. Although she was treated with chemotherapy (weekly paclitaxel and chemotherapeutic regimen of irinotecan + mitomycin C), the tumor was resistant to second-line and third-line chemotherapy and she died 15 months after surgery. Paclitaxel-carboplatin administration may be an effective treatment for primary SCC of the ovary but further studies are required to investigate it true efficacy in the treatment of this disease.
Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Carboplatin/therapeutic use , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/drug therapy , Endometriosis/complications , Endometriosis/drug therapy , Ovarian Neoplasms/complications , Ovarian Neoplasms/drug therapy , Paclitaxel/therapeutic use , Carcinoma, Squamous Cell/diagnosis , Endometriosis/diagnosis , Female , Humans , Laparotomy , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Ovarian Neoplasms/diagnosis , Pelvic Neoplasms/diagnosis , Pelvic Neoplasms/pathologyABSTRACT
A 52-year-old woman with recurrent high-grade endometrial stromal sarcoma presented with left hypochondralgia. She had undergone total hysterectomy and bilateral salpingo-oophorectomy for the disease over the past six months, and preferred not to receive additional treatment. The following regimen of chemotherapy was given: each course consisted of ifosfamide (1,000 mg/m²) on days 1-5, adriamycin (60 mg/m²) on day 1, and cisplatin (15 mg/m²) on days 1-5. After 4 courses of the chemotherapy, the intraabdominal mass and multiple pulmonary nodules were reduced 45. 1% from the beginning. This case suggests that IAP might be effective chemotherapy for patients with high-grade endometrial stromal sarcoma.
